How are we doing? Tracking pharma product launch ROI through global and local challenges

Posted by Andre Moa on Aug 23, 2016 12:00:00 PM

How are we doing Tracking pharma product launch ROI through global and local challenges.jpg

With product margins under pressure in an increasingly complex marketplace, pharmaceutical companies must ensure that each component of their product launch plan makes a meaningful contribution to return on investment (ROI).

 

Read More

Topics: Pharma ROI

Maintaining pharma ROI as market access bites

Posted by Andre Moa on Jun 15, 2016 12:00:00 PM

How can renewed R&D productivity, delivering better targeted, more effective compounds in areas of unmet need, result in lower average margins for pharmaceutical product launches?

Read More

Topics: Pharma ROI, Pharma market access

Making launches count: pharma ROI under strain

Posted by Andre Moa on Apr 21, 2016 12:00:00 PM

 

Medicines need to make a profit. Even the staunchest pharma industry critics, those who would rather see healthcare business as an oxymoron, would have difficulty coming up with a model that did not involve some element of return on investment (ROI) from the money and resources invested in drug discovery, development and commercialisation.

Read More

Topics: Pharma ROI

5 signs your launch team is not collaborating effectively

Posted by Andre Moa on Nov 14, 2014 2:46:00 PM

 

Read More

Topics: Pharma ROI, global launch team, collaboration

3 ways to get more value from your global value dossier

Posted by Andre Moa on Sep 26, 2014 11:45:00 AM

 

When bringing a new medicine to market, it’s essential that you understand the particular requirements of each payer environment, and based on this understanding demonstrate the value of your product to payers. Failing to do so will result in unnecessary reimbursement restrictions, delays as more evidence is requested or, in a worst-case scenario, may block you from a market altogether.

Read More

Topics: Pharma ROI, Pharma market access